PT  - JOURNAL ARTICLE
AU  - Andrés López-Cortés
AU  - César Paz-y-Miño
AU  - Santiago Guerrero
AU  - Alejandro Cabrera-Andrade
AU  - Stephen J. Barigye
AU  - Cristian R. Munteanu
AU  - Humberto González-Díaz
AU  - Alejandro Pazos
AU  - Yunierkis Pérez-Castillo
AU  - Eduardo Tejera
TI  - OncoOmics approaches to reveal essential genes in breast cancer: a panoramic view from pathogenesis to precision medicine
AID  - 10.1101/638866
DP  - 2019 Jan 01
TA  - bioRxiv
PG  - 638866
4099  - http://biorxiv.org/content/early/2019/05/16/638866.short
4100  - http://biorxiv.org/content/early/2019/05/16/638866.full
AB  - Breast cancer (BC) is a heterogeneous disease where each OncoOmics approach needs to be fully understood as a part of a complex network. Therefore, the main objective of this study was to analyze genetic alterations, signaling pathways, protein-protein interaction networks, protein expression, dependency maps and enrichment maps in 230 previously prioritized genes by the Consensus Strategy, the Pan-Cancer Atlas, the Pharmacogenomics Knowledgebase and the Cancer Genome Interpreter, in order to reveal essential genes to accelerate the development of precision medicine in BC. The OncoOmics essential genes were rationally filtered to 144, 48 (33%) of which were hallmarks of cancer and 20 (14%) were significant in at least three OncoOmics approaches: RAC1, AKT1 CCND1, PIK3CA, ERBB2, CDH1, MAPK14, TP53, MAPK1, SRC, RAC3, PLCG1, GRB2, MED1, TOP2A, GATA3, BCL2, CTNNB1, EGFR and CDK2. According to the Open Targets Platform, there are 111 drugs that are currently being analyzed in 3151 clinical trials in 39 genes. Lastly, there are more than 800 clinical annotations associated with 94 genes in BC pharmacogenomics.